The increasing prevalence of multidrug-resistant (MDR) nosocomial infections accounts for increased morbidity and mortality of such infections. Infections with MDR Gram-negative isolates are frequently treated with colistin. Based on recent pharmacokinetic studies, current colistin dosing regimens may result in a prolonged time to therapeutic concentrations, leading to suboptimal and delayed effective treatment. In addition, studies have demonstrated an association between an increased colistin dose and improved clinical outcomes. However, the specific dose at which these outcomes are observed is unknown and warrants further investigation. This retrospective study utilized classification and regression tree (CART) analysis to determine the dose of colistin most predictive of global cure at day 7 of therapy. Patients were assigned to high-and low-dose cohorts based on the CART-established breakpoint. The secondary outcomes included microbiologic outcomes, clinical cure, global cure, lengths of intensive care unit (ICU) and hospital stays, and 7-and 28-day mortalities. Additionally, safety outcomes focused on the incidence of nephrotoxicity associated with high-dose colistin therapy. The CART-established breakpoint for high-dose colistin was determined to be >4.4 mg/kg of body weight/day, based on ideal body weight. This study evaluated 127 patients; 45 (35%) received high-dose colistin, and 82 (65%) received low-dose colistin. High-dose colistin was associated with day 7 global cure (40% versus 19.5%; P ‫؍‬ 0.013) in bivariate and multivariate analyses (odds ratio [OR] ‫؍‬ 3.40; 95% confidence interval [CI], 1.37 to 8.45; P ‫؍‬ 0.008). High-dose colistin therapy was also associated with day 7 clinical cure, microbiologic success, and mortality but not with the development of acute kidney injury. We concluded that high-dose colistin (>4.4 mg/kg/day) is independently associated with day 7 global cure.
T
here has been an increasing prevalence of severe multidrugresistant (MDR) nosocomial infections (1) . MDR isolates, specifically Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, account for high morbidity and mortality (2) . In fact, the Centers for Disease Control and Prevention (CDC) estimate the annual number of cases of infection with carbapenem-resistant Enterobacteriaceae in the United States to be 9,300, and among those, death is the result in 610 cases; this number is only expected to grow (3) . Among critically ill patients, resistant pathogens are consistently associated with worsened outcomes, including increased mortality, prolonged length of hospital stay, and increased hospital cost, compared to those of patients infected with susceptible microorganisms (2, 4) . This is particularly troublesome in an era of few new antimicrobial agents in the research and development pipeline (5) . As such, clinicians are increasingly resorting to colistin as a primary treatment option for MDR organisms.
Colistin (polymyxin E) is a polymyxin antibiotic first used in clinical practice more than 50 years ago. It is administered as a prodrug (colistimethate) that needs to be hydrolyzed to its active form (colistin) in vivo. As a result of its early discovery, it has never been subjected to contemporary drug development procedures (1) . As such, the colistin dosing recommendations provided in package labeling may not reliably result in the serum concentrations necessary for optimal drug activity. In recent years, many new investigations have provided considerable insights into the pharmacodynamic (PD) and pharmacokinetic (PK) properties of colistin. It is thought that the PD profile of colistin is best described as concentration dependent (4, 6) . Furthermore, the ratio of the area under the curve to the MIC (AUC/MIC ratio) is the best PK-PD index to describe the efficacy profile of colistin, with a target of 50 to 65 mg · h/liter (1, 4, 7) . Recent PK studies demonstrated that dosing regimens recommended in package labeling result in subtherapeutic concentrations leading to suboptimal and delayed effective treatment (8, 9) .
Furthermore, recent studies have shown that a higher colistin dose is linked to improved patient outcomes. Several recent investigations demonstrated improvements in clinical cure, microbiologic success, and mortality associated with the use of a higher colistin dose (10) (11) (12) . Despite a link between colistin dose and clinical and microbiologic outcomes, the specific dose at which improved outcomes are observed is unknown, thus warranting further investigation. As such, this study sought to determine the dose of colistin associated with improved global cure rates in patients with Gram-negative bacteremia.
MATERIALS AND METHODS
A retrospective cohort study was performed on all patients at a large academic tertiary care medical center who received intravenous colistin for at least 72 h for the treatment of a carbapenem-resistant Gram-negative bacterium (CR-GNB) bloodstream infection (BSI) from January 2007 to April 2014. Carbapenem resistance was defined based on Clinical Laboratory Standards Institute (CLSI) guidelines for carbapenem resistance, with a MIC of Ն1 g/ml for ertapenem or 2 g/ml for doripenem, imipenem, or meropenem considered to indicate resistance. A modified Hodge test was performed on all Enterobacteriaceae isolates. Patients with a positive blood culture for CR-GNB were identified through a microbiology database. Patients were excluded if they were less than 18 years of age, received colistin for less than 72 h, or had a polymicrobial bacteremia. Furthermore, only the first bacteremic episode that met all inclusion criteria was included. This study was approved by the local institutional review board.
After inclusion, patients were divided into two groups, based on whether they received high-dose or low-dose colistin as determined by classification and regression tree (CART) analysis. Daily colistin dose and renal function information were collected throughout the treatment period. The daily dose of colistin was adjusted based on each patient's daily renal function. See Table 1 for equivalent dosing based on institutional guidelines for colistin dosing. Patients with renal dysfunction had their total daily doses multiplied by a factor (based on their calculated creatinine clearance or their use of dialytic therapy) to calculate the adjudicated total daily dose. As an example, for a patient on intermittent hemodialysis receiving colistin at 1 mg/kg of body weight in a 24-h period, the dose was adjudicated to 3 mg/kg for the purpose of this study. The mean daily colistin dose for each patient was the input for the CART analysis. The colistin dose was reported in milligrams of colistin base activity (CBA). The weight used throughout the analysis of results was ideal body weight (IBW), in kilograms. The following formulas were used to calculate ideal body weight: (i) male IBW ϭ 50 kg ϩ (2.3 ϫ every inch over 5 feet) and (ii) female IBW ϭ 45.5 kg ϩ (2.3 ϫ every inch over 5 feet) (13) .
The primary objective was to determine if high-dose colistin therapy, reported in milligrams per kilogram per day, independently predicts global cure at day 7 of therapy. Global cure was defined as meeting the criteria for both clinical and microbiologic cure. Clinical cure was defined as having a white blood cell count of Ͻ12,000 cells/mm 3 , being afebrile for at least 48 h, and being hemodynamically stable without the need for vasopressors. Clinical failure was defined as failure to meet all criteria for clinical cure. Microbiologic cure was defined as eradication of the original causative organism from subsequent blood cultures at day 7 of therapy, whereas microbiologic failure was defined as persistence of the original causative organism in the subsequent blood cultures by day 7. Secondary objectives included evaluating the effects of high-dose colistin on microbiologic outcomes at day 7 of therapy, day 7 mortality, day 28 mortality, lengths of intensive care unit (ICU) and hospital stays, and incidence of nephrotoxicity. Nephrotoxicity was based on the risk, injury, failure, loss of kidney function, and end-stage kidney disease (RIFLE) criteria and was assessed on day 7 and day 30 after the initiation of colistin (14) . Patients with baseline end-stage renal disease were excluded from the nephrotoxicity analysis.
Data collected from each patient's medical record included demographics (age and gender), height, weight, components of the Pitt bacteremia score (PBS) (15) , components of the Charlson comorbidity index (CCI) (16) , components of the sequential organ failure assessment (SOFA) score (17) , culture data, source of bacteremia (as documented in the medical record by the treating physicians), daily colistin dose, concomitant antibiotic therapy (defined as any aminoglycoside, carbapenem, tigecycline, or other agent that was added to colistin therapy within 24 h of colistin initiation), timing of antibiotic therapy, daily temperature and white blood cell count, and mortality. The source of bacteremia was further categorized based on associated risks for mortality as previously described (18) . Renal function was assessed at day 1 and day 7 of colistin therapy by documenting serum creatinine and the use of renal replacement therapy. The use of renal replacement therapy was also documented at day 30. Concomitant nephrotoxins administered with colistin were also documented (19) .
Statistics. The linear by linear association between daily colistin dose and global cure at 7 days was assessed using the Mantel-Haenszel chisquare test. Subsequently, CART analysis identified the colistin dose that is most predictive of global cure, which served as the breakpoint for highversus low-dose colistin. All subsequent comparisons were done based on high-versus low-dose cohorts. Categorical data were analyzed using either the chi-square test or Fisher's exact test, as appropriate. Continuous data were analyzed using the Mann-Whitney U test. The Mann-Whitney U test was chosen for continuous data as a conservative measure because of the challenge of determining normality with a small data set. The primary objective was assessed using multivariate logistic regression to assess for independent predictors of global cure. Factors entered into the multivariate logistic model included colistin dose and any baseline differences between groups that had P values of Ͻ0.1 on bivariate analysis. A correlation matrix was utilized, and factors which were colinear were systematically eliminated from the final multivariate logistic regression to preserve the overall predictive ability of the model. All statistical analyses were performed using SPSS, version 15.0, for Windows (SPSS Inc., Chicago, IL).
RESULTS

Patients.
Two hundred twelve patients met the initial electronic screening criteria of having a carbapenem-resistant Gram-negative bacteremia and receiving colistin during their stay. Of these 212 patients, a total of 127 patients met the inclusion criteria for the study, and 85 patients were excluded because the colistin duration was Ͻ72 h (82 patients) or because of polymicrobial bacteremia (3 patients).
The CART-established breakpoint for high-dose colistin was Ͼ4.4 mg/kg/day based on IBW. According to the CART-determined dose breakpoint, 45 (35%) patients received high-dose colistin and 82 (65%) patients received low-dose colistin. Patients' baseline characteristics, microbiologic characteristics, and treatment details are shown in Table 2 . Overall, patients were well matched between groups, except that patients in the high-dose colistin group tended to be older (median of 63 years versus 58 years; P ϭ 0.087), were more often female (62% versus 44%; P ϭ 0.048), had a lower IBW (median of 59 kg versus 67 kg; P ϭ 0.030), and less frequently required mechanical ventilation (60% versus 78%; P ϭ 0.031). Baseline severities of illness scores and comorbidities were similar between groups. Furthermore, there was no difference in the type of organism based on colistin dose, median MIC (2 g/ml for both groups; P ϭ 0.63), or source of bacteremia. Among the treatment characteristics, there were no differences in the use of combination antimicrobials; however, the duration of colistin treatment was longer among those treated with high-dose colistin (median of 10.4 days versus 6.5 days; P ϭ 0.028).
Outcomes. Utilizing the Mantel-Haenszel chi-square test, there was a linear by linear association with daily colistin dose correlating with overall global cure (P ϭ 0.035) (Fig. 1) . Overall, 18 (40%) patients in the high-dose colistin group achieved global cure, compared to 16 (19.5%) patients in the low-dose group (P ϭ Table 4 . Overall, high-dose colistin was associated with improvements in day 7 clinical cure, day 7 microbiologic success, and day 7 mortality. However, mortalities at day 28 were not significantly different between the groups. Lengths of hospital and ICU stays were also similar. No difference in the incidence of acute kidney injury (AKI) was observed between groups at day 7 or day 30 (19.5% in the low-dose colistin group versus 31.1% in the high-dose colistin group [P ϭ 0.141] for day 7 and 7.3% in the low-dose colistin group versus 8.9% in the high-dose colistin group [P ϭ 0.753] for day 30). Usages of concomitant nephrotoxins between the groups were also similar (Table 5) .
DISCUSSION
The main result of this retrospective study examining patients treated with colistin for CR-GNB bacteremia is that treatment with colistin doses of Ͼ4.4 mg/kg/day based on IBW results in improvements in day 7 global cure, without a significant difference in the development of renal dysfunction. In a multivariate analysis, after adjusting for baseline discrepancies, high-dose colistin was the only factor independently associated with day 7 global cure.
The results of the current study are in agreement with several previous investigations. In a retrospective, single-center cohort study by Falagas and colleagues (11) , it was concluded that mortality among patients who received an average daily colistin dose of 3 million IU (100 mg CBA) (38.6%) was higher than the mortality among patients who received 6 million IU (200 mg CBA) (27.8%) and patients who received 9 million IU (300 mg CBA) (21.7%). Not only was there a difference in the dose of colistin between survivors and nonsurvivors, but the average daily dose of colistin was an independent predictor for mortality, with high colistin dose being associated with an increased probability of survival (adjusted OR [aOR] ϭ 1.22; 95% CI, 1.05 to 1.42; P ϭ 0.009) (11) . However, the exact dose associated with increased survival probability was not elucidated by the authors. Subsequently, a study by Dalfino and colleagues (10) treated patients with a dosing schedule involving a loading dose of 9 million units (300 mg CBA) and a maintenance dose of 4.5 million units (150 mg CBA) every 12 h. This dosing regimen led to a clinical cure rate of 82%, which is the highest reported clinical cure rate reported for the use of systemic colistin for the treatment of multidrug-resistant Gramnegative infections (10) . One of our previous studies similarly concluded that an increased dose of colistin independently predicts day 7 microbiologic success (2.9 versus 1.5 mg/kg/day; P ϭ 0.11) and is correlated with day 7 mortality (2.7 versus 1.5 mg/kg/ day; P ϭ 0.007) (12) . The global cure rate of 40% in the current study is lower than that observed in previous studies, which may be attributable to our more stringent definition of global cure. In contrast to previous studies, which required either clinical improvements (10) or microbiological clearance (12), our definition for global cure required the combination of both criteria. The association between higher doses of colistin and improved clinical outcomes also corroborates well with recent PK and PD investigations. Several investigations have demonstrated that administration of colistin at package labeling-recommended doses results in suboptimal pharmacodynamic target attainment for many strains of Gram-negative bacilli reported to be sensitive to colistin (4, 8, 9, 16) . Based on the PK and PD evaluations, several investigations have attempted to model the most appropriate dose of colistin. Realizing that traditional twice-or thrice-daily dosing would require up to 3 days to reach steady-state target levels, Plachouras and colleagues, using a population PK analysis, recommended a loading dose of 300 to 400 mg CBA followed by a maintenance dose of 150 mg twice daily to reach serum concentration targets earlier (20) . Similarly, Garonzik and colleagues conducted a PK study of colistin in 105 critically ill patients, and they discovered that only 12% of patients achieved steady-state colistin concentrations above the PD goal (1). Based on PK modeling, Garonzik et al. concluded that a loading dose based on the target colistin concentration and a maintenance dose based on renal function and the target concentration should be utilized. Note that the doses recommended based on the equations provided would result in significantly higher colistin doses than those outlined in the package insert. In summary, studies have demonstrated the failure of current dosing recommendations to reach PD goals, PK modeling studies suggest an increased dose regimen to attain PD goals, and the current study demonstrates clinically the association between increased dose and global cure. Furthermore, the dose cutoff for improved benefit observed in the current study is similar to those recommended by the PK modeling studies (4, 8, 9, 20) .
The previous studies all suggested that higher doses of colistin than those currently recommended in the package labeling may provide additional outcome benefits. However, those studies did not elucidate the dose that is most associated with improvements in outcome. By using CART analysis, the current study was able to determine a cutoff of 4.4 mg/kg/day by IBW (about 300 mg CBA per day for a patient with an IBW of 70 kg) to be most predictive of improvements in global cure rates. Another unique aspect of the current study is the incorporation of dose adjustments and adjudication of doses based on renal function, which were not discussed in the previous studies (11, 12) . Recent advances in the understanding of colistin elimination provide further insights into the need for renal adjustments (21) . For example, the maintenance doses of colistin recommended by the package labeling are able to achieve plasma concentrations of 4 to 9 mg/liter in patients with renal dysfunction (21) because colistimethate, a prodrug that is renally eliminated, needs to be hydrolyzed to the active compound, colistin, which is not renally eliminated. As such, patients with renal dysfunction have delayed elimination of colistimethate, which leads to higher in vivo conversion to colistin (22) . Therefore, renal dose adjustments are necessary. However, to date, few clinical studies have elucidated the proper dose adjustments necessary and whether those dose adjustments do in fact lead to outcome benefits. The dose adjustments utilized in the current study represent the local recommendations that were employed during the study and may represent a reasonable clinical approach to colistin renal dosing. This study has several limitations. Due to the retrospective nature of the study, there may be unaccounted baseline differences between groups. The design of the study excluded patients who received colistin for Ͻ72 h, which may have excluded patients who died shortly after the receipt of colistin. This exclusion criterion was incorporated because it would be difficult to ascertain the effects of colistin on global cure if therapy for a shorter period were included, and previous studies utilized similar inclusion criteria (11) . A second limitation, which is common to all single-center dosing studies that evoke PK-PD relationships, is the external validity of the findings. The current study can ultimately make firm dosing conclusions based only on the local pathogen epidemiology. PD relationships and PD targets are concerned with how the drug interacts with the pathogen, which may have epidemiologic patterns and MICs different from those in other institutions. In our study, the range of colistin MICs was 0.5 to 2 g/ml, which is similar to those at other centers (23) . However, the current findings may not be applicable to institutions with dramatically different colistin MICs. Furthermore, colistin dose adjustments based on renal function are not universally accepted. The dose cutoff that was found in the current study was based on a renal dose adjudication that was utilized locally. Hence, the results may also differ in an institution where renal dose adjustments are performed differently. Lastly, based on the definition of AKI, not all patients were eligible for analysis, and therefore the study may have been underpowered to evaluate this outcome.
Conclusions. This study demonstrates that the use of highdose colistin, defined as a dose of Ͼ4.4 mg/kg/day, independently predicts day 7 global cure. Furthermore, patients who received high-dose colistin had greater 7-day survival, clinical cure, and microbiologic success than those who received low-dose colistin. In the era of limited treatment options for carbapenem-resistant pathogens, the medical community must optimize the available therapies. The current study, in conjunction with previous works, may provide the framework necessary for a definitive prospective study with clear colistin dosing recommendations and renal dose adjustments. 
